Imagen de Portada

Editorial: Does Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD ) With Advanced Fibrosis Also Equate to Risk of Advanced Coronary Artery Disease?

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	C. C. Mark Cheah, B. B. George Goh
Formato:	Artículo Open Access
Publicado:	Wiley 2025
Materias:	Alimentary Pharmacology & Therapeutics
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Editorial: Does Metabolic Dysfunction‐Associated Steatotic Liver Disease With Advanced Fibrosis Also Equate to Risk of Advanced Coronary Artery Disease? Authors' Reply
por: Xiao‐Dong Zhou, et al.
Publicado: (2025)

Letter on ‘Inherited Genetic Risk of Liver Fibrosis in Lean Versus Nonlean Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD )’; Authors’ reply
por: Kaleb Tesfai, et al.
Publicado: (2026)

Anthropometric Measures and Mortality Risk in Individuals With Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD): A Population‐Based Cohort Study
por: Yee Hui Yeo, et al.
Publicado: (2025)

Editorial: Comparable Hepatic Fibrosis Risk Demands Equal Vigilance in Lean and Non‐Lean Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease
por: Shinya Yokoyama, et al.
Publicado: (2025)

Prevalence and Predictors of Suspected Metabolic Dysfunction‐Associated Steatotic Liver Disease in Adolescents in the United States
por: Sheila L. Noon, et al.
Publicado: (2025)

Editorial: Comparable Hepatic Fibrosis Risk Demands Equal Vigilance in Lean and Non‐Lean Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease—Authors' Reply
por: Kaleb Tesfai, et al.
Publicado: (2025)

Letter: Combination Therapies With Vitamin E for Metabolic Dysfunction‐Associated Steatotic Liver Disease
por: Stergios A. Polyzos, et al.
Publicado: (2024)

Association of High‐Sensitivity Troponins in Metabolic Dysfunction‐Associated Steatotic Liver Disease With All‐Cause and Cause‐Specific Mortality
por: Donghee Kim, et al.
Publicado: (2025)

Gastrointestinal Cancer Risk in Steatotic Liver Diseases: MASLD , MetALD and ALD
por: Nobuharu Tamaki, et al.
Publicado: (2025)

Meta‐Analysis: Global Prevalence and Mortality of Cirrhosis in Metabolic Dysfunction‐Associated Steatotic Liver Disease
por: Soroor Owrangi, et al.
Publicado: (2024)

Alcohol–Related Liver Disease, Followed by Metabolic Dysfunction–Associated Steatotic Liver Disease, Emerges as the Fastest‐Growing Aetiologies for Primary Liver Cancer in the United States
por: Pojsakorn Danpanichkul, et al.
Publicado: (2025)

Liver Fibrosis and the Risk of Coronary Artery Disease, Stent Thrombosis, Restenosis and Adverse Clinical Outcomes
por: Na Tian, et al.
Publicado: (2025)

Editorial: Evaluating the Prevalence of Metabolic Dysfunction‐Associated Steatotic Liver Disease in Patients With Type 2 Diabetes and Hyperferritinaemia—Authors' Reply
por: Maral Amangurbanova, et al.
Publicado: (2024)

Editorial: Prevalence of Suspected Metabolic Dysfunction‐Associated Steatotic Liver Disease in Adolescents in the United States Using Updated Diagnostic Criteria
por: Julie Bonn, et al.
Publicado: (2025)

Social Determinants of Health in Metabolic Dysfunction‐Associated Steatotic Liver Disease and All‐Cause/Cause‐Specific Mortality
por: Donghee Kim, et al.
Publicado: (2025)

Letter: Global Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease‐Related Liver Cancer—Results From the Global Burden of Disease Study 2021
por: Chunlong Liu, et al.
Publicado: (2025)

Letter: Comparison of the Efficacy of Adjuvant PD‐1 Inhibitor After Curative Resection for Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) Related HCC Versus Other Aetiologies
por: Jia‐Yong Su, et al.
Publicado: (2025)

Editorial: Hyperferritinaemia—An Ironclad Biomarker for the Prognostication of MASLD?
por: Mark C. C. Cheah, et al.
Publicado: (2025)

Predicting Hepatic Decompensation in Patients With Metabolic Dysfunction Associated Steatotic Liver Disease‐Related Cirrhosis: The ABID‐LSM Model
por: Luis Calzadilla Bertot, et al.
Publicado: (2025)

Extracellular Vesicles miRNome Profiling Reveals miRNAs Engagement in Dysfunctional Lipid Metabolism, Chronic Inflammation and Liver Damage in Subjects With Metabolic Dysfunction‐Associated Steatotic Liver Disease
por: Gian Paolo Caviglia, et al.
Publicado: (2025)

Advanced Fibrosis and Cardiometabolic Risk Burden Increase Major Cardiovascular Events in Chronic Hepatitis C Patients With Steatotic Liver Disease After Viral Eradication
por: Pei‐Chien Tsai, et al.
Publicado: (2025)

Editorial: Time to Genotype—Genetic Risk and Prognosis in Steatotic Liver Disease
por: Rosellina M. Mancina, et al.
Publicado: (2025)

Editorial: Revolutionising Steatotic Liver Disease Diagnosis With Phosphatidylethanol
por: Karen Cheuk‐Ying Ho, et al.
Publicado: (2025)

Editorial: Liver and Non‐Liver Outcomes Between Different Subtypes of Steatotic Liver Disease
por: Jee‐Fu Huang, et al.
Publicado: (2026)

Editorial: Prevalence of Suspected Metabolic Dysfunction‐Associated Liver Disease in Adolescents in the United States Using Updated Diagnostic Criteria—Authors' Reply
por: Sheila L. Noon, et al.
Publicado: (2025)

The Prevalence and Risk Factors for at‐Risk MASH and Advanced Liver Fibrosis in People With Metabolic Risk Factors in Primary Care
por: Leon A. Adams, et al.
Publicado: (2026)

Editorial: Two Common Risks, One Greater Harm—Diabetes and Alcohol in Steatotic Liver Disease
por: Stine Johansen, et al.
Publicado: (2026)

Editorial: Revolutionising Steatotic Liver Disease Diagnosis With Phosphatidylethanol—Authors' Reply
por: Federica Tavaglione, et al.
Publicado: (2025)

Letter: Comparing the Efficacy of Adjuvant PD–1 Inhibitor After Curative Resection for Metabolic Dysfunction‐Associated Steatotic Liver Disease Related HCC Versus Other Aetiologies—Authors' Reply
por: Isabella Lurje, et al.
Publicado: (2025)

Editorial: Steatotic Liver Diseases Emerge as Rapidly Growing Drivers of Primary Liver Cancer in the United States
por: Kelly Torosian, et al.
Publicado: (2025)

Coronary Artery Disease and Major Adverse Cardiovascular Events in People With Hepatic Steatosis at Low Atherosclerotic Cardiovascular Disease Risk
por: Julia Karady, et al.
Publicado: (2024)

Letter: Myokines Are Also Associated With Disease Course in Primary Biliary Cholangitis
por: Leyu Zhou, et al.
Publicado: (2024)

Persistent Binge Drinking History Associated With Advanced Liver Fibrosis and All‐Cause Mortality in MetALD
por: Zhe‐Kun Xiong, et al.
Publicado: (2025)

Editorial: ICG ‐ R15 by PDD —A Simple Dynamic Tool for Refining Risk Stratification in Compensated Advanced Chronic Liver Disease
por: Yixuan Zhu, et al.
Publicado: (2025)

Subtype Differences in Major Adverse Liver Outcomes and Cardiovascular Events and Mortality in Steatotic Liver Disease: A UK Biobank Analysis
por: Takao Miwa, et al.
Publicado: (2026)

Safety and Tolerability of Injectable Extended‐Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol‐Associated Liver Disease
por: Luis Antonio Díaz, et al.
Publicado: (2025)

Overall and Comparative Risk of Shingles With Advanced Therapies in Patients With Inflammatory Bowel Diseases
por: Dhruv Ahuja, et al.
Publicado: (2025)

Biomarkers of Extracellular Matrix Remodelling Are Linked to Severity and Outcome of Advanced Chronic Liver Disease
por: Benedikt Simbrunner, et al.
Publicado: (2025)

Letter: Safety and Tolerability of Injectable Extended Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol‐Associated Liver Disease
por: Xing Bai, et al.
Publicado: (2025)

Indocyanine Green Clearance Correlates With Biomarkers Reflecting Key Disease‐Driving Mechanisms in Advanced Chronic Liver Disease and Predicts Acute‐on‐Chronic Liver Failure and Death
por: Mathias Jachs, et al.
Publicado: (2025)